Research programme: metal-protein-attenuating compounds - Prana Biotechnology

Drug Profile

Research programme: metal-protein-attenuating compounds - Prana Biotechnology

Alternative Names: MPAC - Prana Biotechnologies; PBT 519; PBT-434; PBT3 series - Prana Biotechnologies; PBT4 series - Prana Biotechnologies

Latest Information Update: 08 Mar 2016

Price : $50

At a glance

  • Originator Prana Biotechnology
  • Class Quinazolinones
  • Mechanism of Action Alpha-synuclein inhibitors; Iron chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Alzheimer's disease; Brain cancer; Parkinson's disease; Parkinsonian disorders
  • Research Neurodegenerative disorders

Most Recent Events

  • 26 Feb 2016 Prana Biotechnology plans a phase I trial for Parkinsonian disorders
  • 26 Feb 2016 Prana Biotechnology announces intention to submit IND for PBT 434
  • 29 Sep 2015 Early research in Neurodegenerative disorders in Australia (unspecified route) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top